Ken Griffin Moon Lake Immunotherapeutics Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Citadel Advisors LLC holds 9,100 shares of MLTX stock, worth $444,899. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,100
Previous 11,500
20.87%
Holding current value
$444,899
Previous $611,000
41.9%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding MLTX
# of Institutions
160Shares Held
55.2MCall Options Held
481KPut Options Held
229K-
Bvf Inc San Francisco, CA19.8MShares$966 Million33.91% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$415 Million35.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.97MShares$145 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$135 Million1.75% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.43MShares$70.1 Million0.29% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.81B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...